Daniel Patrick O’day Sells 15,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, July 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00.
• On Monday, June 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00.

Gilead Sciences Price Performance

GILD stock opened at $131.76 on Thursday. The stock’s 50 day moving average is $129.54 and its two-hundred day moving average is $136.18. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a market capitalization of $163.59 billion, a PE ratio of -49.35 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 1.86% and a negative net margin of 10.64%.The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the business posted $2.01 EPS. The business’s revenue was up 10.6% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.80 billion, above the approximately $7.40 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by double-digit HIV growth and continued momentum in Trodelvy. Gilead Q2 Earnings Beat on HIV and Trodelvy Growth
• Positive Sentiment: Management raised its HIV growth outlook to 9%-10% and lifted its 2026 base-business sales outlook to approximately $29.8 billion-$30.1 billion. Yeztugo, Gilead’s HIV PrEP treatment, generated roughly $1 billion in sales as uptake accelerated. Gilead Raises HIV Growth Outlook
• Positive Sentiment: Needham reaffirmed its Buy rating with a $170 price target, while Cantor Fitzgerald maintained Overweight and a $155 target, indicating potential upside if HIV and oncology growth continues.
• Positive Sentiment: Gilead declared its quarterly dividend of $0.82 per share, supporting the stock’s income appeal. The dividend is payable September 29 to shareholders of record September 15.
• Neutral Sentiment: Gilead’s full-year EPS outlook improved relative to consensus, but revenue guidance of $30.1 billion-$30.4 billion remained slightly below analysts’ $30.5 billion estimate, reflecting acquisition and research spending.
• Negative Sentiment: The company posted a $6.75-per-share quarterly loss versus $2.01 of earnings a year earlier. Acquisition-related charges and research-and-development costs overshadowed the operating improvement and raised concerns about deeper 2026 losses. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment and highlighting pressure from a declining product. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: AIDS Healthcare Foundation criticized Gilead’s HIV pricing and licensing policies, creating potential reputational and access-related risks in global markets. RBC maintained a Sector Perform rating with a $123 target, below the current valuation.
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction is a limited signal because it was scheduled in advance, but it may add to investor caution.

Institutional Trading of Gilead Sciences

Several institutional investors have recently added to or reduced their stakes in GILD. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after buying an additional 2,113,692 shares during the period. State Street Corp grew its position in shares of Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after buying an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the period. Bank of America Corp DE lifted its holdings in Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Finally, Norges Bank bought a new position in Gilead Sciences in the fourth quarter worth about $2,617,152,000. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GILD shares. Morgan Stanley dropped their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Truist Financial lowered their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Finally, Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.